Group items tagged

The Lords Food, Diet and Obesity Committee has expressed disappointment with the government's response to its recommendations for tackling the obesity crisis. In October 2024, the Committee released its report, Recipe for Health: A Plan to Fix Our Broken Food System, following a special inquiry. The report identified obesity and diet-related diseases as a public health emergency, costing society billions annually in healthcare expenses and lost productivity. It urged the government to develop a "comprehensive, integrated long-term new strategy to fix the food system", supported by a new legislative framework and outlined key actions that should be included. The government published its response to the report on 30 January 2025, but the Committee criticized it for lacking boldness and delaying many necessary measures. Baroness Walmsley, who chaired the Committee said: "In recent interviews with researchers, former prime ministers and health secretaries expressed regret that they had not done more to tackle obesity and advised the government to 'be bold and act fast'. "The report from the Lords Food, Diet and Obesity Committee recommended bold measures to be implemented immediately.

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly "opens the possibility of an end to the obesity pandemic" alongside other interventions, the World Health Organisation (WHO) said this week. But the global health agency said it has concerns that unless health systems prepare properly, the drugs could distort the response to the global obesity crisis, risking leaving people behind and overshadowing other steps to improve health. The new drugs "have the potential to be transformative", according to the WHO's chief scientist, Jeremy Farrar, its director of nutrition, Francesco Branca, and his senior adviser, Francesca Celleti, in an opinion piece in the Journal of the American Medical Association (JAMA). The article is the agency's clearest comment yet on the potential of the new drugs, known as GLP-1 receptor agonists. But "medication in isolation will not be enough to address the obesity crisis," they added, calling instead for the innovation to push clinicians, governments, the pharmaceutical industry and the public towards considering the condition a chronic disease that needs further study into how best to prevent and treat it.

More pharmacies should do NHS Health Checks to improve access, a new study that focuses on ways to improve the lives of people living with obesity, recommends. The report, Levelling Up Obesity Care, by pharma giant Novo Nordisk follows a series of roundtables with patient advocates, healthcare professionals and academics to generate understanding on the future of obesity care in England. Amongst its recommendations, the report says that 'to widen access and alleviate pressure on GP services, consideration should be given to expanding NHS Health Checks in community pharmacy'. NHS Health Checks include a measurement of Body Mass Index (BMI). Those most likely to benefit from a Health Check include people who live in more deprived areas, and are more likely to be living with obesity, says the report.

The World Health Organization (WHO) issued a warning on Thursday regarding falsified semaglutide medications used for treating type 2 diabetes and obesity in select countries. This WHO Medical Product Alert addresses three falsified batches of the specific brand Ozempic that were detected in Brazil (October 2023), the United Kingdom and Northern Ireland (October 2023), and the United States (December 2023). These falsified semaglutide products were distributed through the regulated supply chain. Novo Nordisk, the genuine manufacturer of Ozempic, confirmed that the three products mentioned in the alert are falsified and were not produced by the company. Healthcare professionals, regulatory authorities and the public are advised to remain vigilant regarding these falsified batches of medicines. Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products, urged stakeholders to stop any usage of suspicious medicines and report them to relevant authorities.

A diet supplemented with vitamin D can help support healthy weight loss and reduce fat percentage, a new clinical study revealed. A trial was conducted over a three-month period with 125 overweight and obese Southeastern European Caucasians with vitamin D deficiency or insufficiency. Participants were prescribed vitamin D3 3000 IU/d oral spray supplementation, or a placebo, alongside a calorie-restricted diet programme of 600 kcal less than the total energy expenditure of each individual. The report stated that the group who were prescribed vitamin D witnessed significant improvements in serum 25(OH)D level and a greater reduction in body weight, BMI, and fat percentage in all individuals within this group. The study supported by BetterYou found that with the prevalence of low vitamin D becoming a serious global health problem in all ages, even in areas with natural sun exposure throughout the year, the study shines a light on the importance of vitamin D supplementation.